BioSpace News Archive

Alcon, the global leader in eye care, reported its financial results for the three and six months ended June 30, 2022.

Liminal BioSciences Inc. (Nasdaq: LMNL) (“Liminal BioSciences” or the “Company”), today reported its financial results for the second quarter ended June 30, 2022.

Taysha Gene Therapies, Inc. announced that it will report its financial results for the second quarter ended June 30, 2022, and host a corporate update conference call and webcast on Thursday, August 11, 2022, at 8:00 AM Eastern Time.

Aziyo Biologics, Inc., a commercial-stage regenerative medicine company, announced that Aziyo co-founder C. Randal Mills, Ph.D. has assumed the President and Chief Executive Officer role on an on-going basis.

Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today reported financial results for the second quarter ended June 30, 2022 and provided an update on its corporate activities and product pipeline.

Catalent, Inc. announced that it has reached an agreement to acquire Metrics Contract Services, a full-service specialty Contract Development and Manufacturing Organization with a facility in Greenville, North Carolina, for $475 million from Mayne Pharma Group Limited .

Mirum Pharmaceuticals, Inc., a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and orphan diseases, announced the pricing of its previously announced underwritten public offering of 3,478,261 shares of its common stock at a price to the public of $23.00 per share.

Verona Pharma plc, a clinical-stage biopharmaceutical company focused on respiratory diseases, announced a proposed underwritten public offering of 10 million American Depositary Shares, each representing eight ordinary shares of Verona Pharma, nominal value £0.05 per share.

Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), today announced the advancement of OP-1250, a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), into Phase 2 clinical development for the treatment of ER+/HER2- metastatic breast cancer.

Akumin Inc. (NASDAQ: AKU) (TSX: AKU) (“Akumin” or the “Company”), a national partner of choice for U.S. hospitals, health systems and physician groups with comprehensive solutions addressing outsourced radiology and oncology service line needs, announced today its financial results for the quarter ended June 30, 2022.